• 1
    Lux MP,Fasching PA,Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 2006; 84: 1628.
  • 2
    Zografos GC,Panou M,Panou N. Common risk factors of breast and ovarian cancer: recent view. Int J Gynecol Cancer 2004; 14: 72140.
  • 3
    Easton DF,Pooley KA,Dunning AM,Pharoah PD,Thompson D,Ballinger DG,Struewing JP,Morrison J,Field H,Luben R,Wareham N,Ahmed S, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 108793.
  • 4
    Hunter DJ,Kraft P,Jacobs KB,Cox DG,Yeager M,Hankinson SE,Wacholder S,Wang Z,Welch R,Hutchinson A,Wang J,Yu K, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 8704.
  • 5
    Stacey SN,Manolescu A,Sulem P,Rafnar T,Gudmundsson J,Gudjonsson SA,Masson G,Jakobsdottir M,Thorlacius S,Helgason A,Aben KK,Strobbe LJ, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007; 39: 8659.
  • 6
    Huijts PE,Vreeswijk MP,Kroeze-Jansema KH,Jacobi CE,Seynaeve C,Krol-Warmerdam EM,Wijers-Koster PM,Blom JC,Pooley KA,Klijn JG,Tollenaar RA,Devilee P, et al. Clinical correlates of low risk variants in FGFR2. TNRC9, MAP3K1, LSP1 and 8q24 in a. Dutch cohort of incident breast cancer cases. Breast Cancer Res 2007; 9: R78.
  • 7
    Terry KL,De Vivo I,Titus-Ernstoff L,Shih MC,Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005; 65: 597481.
  • 8
    Hankinson SE,Willett WC,Manson JE,Hunter DJ,Colditz GA,Stampfer MJ,Longcope C,Speizer FE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995; 87: 1297302.
  • 9
    Gates MA,Tworoger SS,Hecht JL,De Vivo I,Rosner B,Hankinson SE. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 2007; 121: 222532.
  • 10
    Tworoger SS,Lee IM,Buring JE,Rosner B,Hollis BW,Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 7838.
  • 11
    DerSimonian R,Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 12
    Dillon C,Spencer-Dene B,Dickson C. A crucial role for fibroblast growth factor signaling in embryonic mammary gland development. J Mammary Gland Biol Neoplasia 2004; 9: 20715.
  • 13
    Grose R,Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 17986.
  • 14
    Steele IA,Edmondson RJ,Bulmer JN,Bolger BS,Leung HY,Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001; 20: 587887.
  • 15
    Steele IA,Edmondson RJ,Leung HY,Davies BR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006; 24: 4553.
  • 16
    Ghoussaini M,Song H,Koessler T,Al Olama AA,Kote-Jarai Z,Driver KE,Pooley KA,Ramus SJ,Kjaer SK,Hogdall E,DiCioccio RA,Whittemore AS, et al. Multiple Loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008; 100: 9626.